X0306 4 2012-12-20 0 0000812796 SOLIGENIX, INC. SNGX 0001092601 SIGMA TAU FINANZIARIA SPA VIA SUDAFRICA, 20 ROME L6 00144 ITALY 0 0 1 0 0001170881 SIGMA TAU INTERNATIONAL SA 19-21 BOULEVARD DU PRINCE HENRI L-1724 LUXEMBOURG N4 LUXEMBOURG 0 0 1 0 0001385930 Sigma-Tau America S.A. 19-21 BOULEVARD DU PRINCE HENRI L-1724 LUXEMBOURG N4 LUXEMBOURG 0 0 1 0 0001385625 Sigma-Tau Pharmaceuticals, Inc. 9841 WASHINGTONIAN BLVD, SUITE 500 GAITHERSBURG MD 20878 0 0 1 0 Common Stock 2711392 I Indirect Common Stock Warrant (right to buy) 5.60 2012-12-20 4 J 0 1 D 2009-09-28 2014-09-27 Common Stock 98813 0 I Indirect Common Stock Warrant (right to buy) 5.60 2012-12-20 4 J 0 1 D 2010-06-18 2015-06-18 CommonStock 258256 0 I Indirect Common Stock Warrant (right to buy) 0.53 2012-12-20 4 J 0 1 A 2013-06-19 2017-12-19 Common Stock 357069 1 I Indirect On February 1, 2012, the Issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-20, whereby every 20 shares of its common stock was exchanged for one share of its common stock (the "Reverse Stock Split"). These shares were previously reported but the numbers have been changed to reflect the Reverse Stock Split. Directly owned by Sigma-Tau Pharmaceuticals, Inc. ("Pharmaceuticals"). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. ("America"). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. ("International"). International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. The exercise prices that were previously reported have been adjusted to reflect the Reverse Stock Split. These three reported transactions involved the issuance by the Issuer to Pharmaceuticals of a new warrant in exchange for the surrender by Pharmaceuticals of outstanding warrants. The expiration date of the warrant may be accelerated at the Issuer's option if the Issuer's common stock meets certain price thresholds and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended. Exhibit List Exhibit 99 - Joint Filer Information /s/ Fabio Amabile 2012-12-21